TP53 and neoplasm: We performed a next-generation sequencing (NGS) panel including TP53 and immunohistochemistry staining using a p53 antibody with an N-terminal epitope (at the transactivation domain) to detect the protein levels, subcellular locations, and additionally, the tumor mosaicism or subclonal heterogeneity.